Further research is necessary to address the limitations of this study, specifically by including a larger and more diverse population with distinct cognitive groupings, such as preclinical AD, MCI, and mild to severe AD, and by incorporating comparisons with other specific biomarkers, including the APOE-ε4 gene, amyloid-β deposition, and the Tau protein. This evidence concerns the gene MAPT and Alzheimer disease.